Article
Analysis of Progression Patterns and Failure Sites of Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations Receiving First-line Treatment of Tyrosine Kinase Inhibitors.
Clinical lung cancer - 1 Nov 2020
Li Xiao-Yang, Zhu Xue-Ru, Zhang Chen-Chen, Yu Wen, Zhang Bo, Shen Tian-le, Zhang Hong-Yan, Fu Xiao-Long
Abstract excerpt
BACKGROUND: Reliable prediction of progression patterns and failure sites for patients with stage IV lung adenocarcinoma is valuable for physicians to deliver personalized tyrosine kinase inhibitor (TKI) treatment. PATIENTS AND METHODS: We retrospectively enrolled 266 patients who had stage IV lung adenocarcinoma and received first-line TKI treatment from 2013 to 2017 in Shanghai Chest Hospital. The clinical...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.